To this end, genome-wide screening of TKI-resistant neoplastic cells will help identify the genetic variations underlying TOPK overexpression and activation, and will help determine whether TOPK acts as a driver or mediator of EGFR-TKI resistance in human lung carcinomas [51]. This evidence concerns the gene PBK and lung carcinoma.